Survey

This month we would like to know...

Fingolimod (Gilenya) was recently FDA approved in the treatment of relapsing remitting multiple sclerosis (RRMS). How is your health system covering or planning on covering this new oral disease-modifying therapy (DMT)?

1) We will be/are covering it only for patients who have failed injectable DMTs (both in the interferon class and glatiramer acetate).

2) We will be/are covering it only for patients who have failed injectable DMTs (either an interferon or glatiramer acetate).

3) We will be/are covering it for patients that meet certain criteria. However, the main criteria does not have to be failure of an injectable DMT.

4) We will be/are covering it for patients with a new diagnosis of RRMS only.

5) We will not be covering it at all until more data is available.

6) We have not yet decided how to cover this product.

Digital Edition

FDA warns about a serious adverse effect associated with the use of benzocaine

FDA issued drug safety communications about a serious adverse effect associated with the use of over-the-counter benzocaine gels, sprays, and liquids applied to the throat and gums to reduce pain. Read full article.

AHA presents guidelines for managing manifestations of VTE

There are several therapies in addition to blood thinners that physicians should consider when managing patients with deep vein thrombosis, according to a new scientific statement from the American Heart Association. Read full article.

FDA approves gabapentin enacarbil
for RLS

FDA has approved gabapentin enacarbil (Horizant Extended-Release Tablets, GlaxoSmithKline and XenoPort), a once-daily treatment for moderate-to-severe restless legs syndrome, also known as Ekbom disease. Read full article.

Vaginal progesterone gel reduces rate of preterm birth

The administration of vaginal progesterone from the mid-trimester of pregnancy until term in women with a premature cervical shortening as confirmed by transvaginal ultrasound significantly reduced the rate of preterm birth before 33 weeks gestation, according to a phase 3 study published online April 6 in Ultrasound in Obstetrics & Gynecology. Read full article.

THERAPY UPDATE

Current and future applications of desirudin: A bivalent, subcutaneous direct thrombin inhibitor

Desirudin is a bivalent direct thrombin inhibitor (DTI) indicated for the prevention of deep-vein thrombosis in patients undergoing elective hip replacement surgery.
It is the only DTI approved for subcutaneous administration. Read full article.

Contact Us

Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.